Jason P Rhodes

DYN director Rhodes executes 9 sales totaling 267,760 shares for $5,646,496.80 under pre-arranged 10b5-1 plan

Jason P Rhodes sold 267,760 shares (267.8K shares) across 9 separate transactions on 2026-06-23 through 2026-06-25 for $5,646,496.80, reducing his holdings from 1,348,804 shares (1.35M shares) to 1,081,044 shares (1.08M shares)—a reduction of -19.9%. This transaction is part of a pre-arranged 10b5-1 trading plan adopted on 2026-03-19, meaning execution is scheduled rather than discretionary. Dyne Therapeutics remains unprofitable with net income of $-120,854,000.00 ($-120.9M) over its most recent full fiscal year. The stock currently trades at $20.61, down -17.6% from its 52-week high of $25.00, though it has risen +13.6% over the past 30 days and +20.2% over 90 days. Rhodes' prior sales at DYN on 2026-05-06 showed a 30-day return of -6.3%, while his cross-ticker track record across 20 prior sells shows an average 30-day return of -1.1%, though outcomes at this specific ticker are limited for measuring predictive value.

Director Rhodes unloads ~$1.9M in DYN shares; stock well below 52-week high amid persistent insider-selling pattern and unprofitable fundamentals.

Jason P. Rhodes, a director of Dyne Therapeutics, disposed of over 106,000 shares across three trading days in early May for approximately $1.9 million total. The stock is currently trading well below its 52-week high, having declined significantly from recent peaks. This sale adds to Rhodes' long-standing pattern of open-market dispositions—he has now executed 83 open-market sales over the past 36 months, with all five of his prior sales at this specific ticker proving poorly-timed, as the stock rose following each exit. Notably, the company is unprofitable with significant annual losses, and Rhodes' sustained selling activity over an extended period suggests a consistent orientation toward reducing exposure rather than conviction about near-term upside. The combination of persistent board-level sales, weak fundamentals, and the director's poor historical timing on prior DYN exits warrants closer scrutiny of whether operational challenges are driving these dispositions.

Director Jason Rhodes sells ~228k shares of DYN for ~$4.2M across multiple tranches on single day

Jason Rhodes, a director at Dyne Therapeutics, executed a substantial multi-tranche sale of approximately 228,000 shares totaling $4.2 million on a single day. The company is currently unprofitable with significant ongoing losses, and the stock is trading well below its highs from earlier in the year. While a sale of this magnitude could suggest a director reducing exposure during a period of negative earnings momentum, the execution across eight separate transactions at marginally different prices is noteworthy—it reads more like portfolio rebalancing or a systematic liquidation plan than a panic exit. The timing coincides with a stock trading modestly above recent lows, which is neutral rather than obviously unfavorable. Without visibility into Rhodes' trade plan authorization or historical selling patterns, this requires closer inspection to determine whether this reflects concern about the company's trajectory or routine personal financial management by a board member.

Director Rhodes sold 384,549 shares (24.2% of holdings) at $18.15–$19.19 over 3 days for $7.1M while DYN remains unprofitable.

Director Jason P Rhodes executed 12 separate sales totaling 384,549 shares for $7,101,119.51 between April 23–27, 2026, reducing his holdings from 1,590,575 shares to 1,206,026 shares. The sales occurred across three trading days at blended average price $18.47, with individual transaction prices ranging from $18.15 to $19.19. The company reported net income of -$108,041,000.00 for its most recent full fiscal year, indicating ongoing unprofitability. Rhodes's prior five sales at DYN (since Feb 2024) showed a 0-of-5 well-timed rate at the 90-day mark, meaning none preceded a subsequent decline; his cross-ticker track record shows an average 90-day return of +23.9% after sales, indicating his prior sells have historically underperformed (stock rose after he sold). The current stock price of $18.04 is -25.7% from the 52-week high of $24.29, suggesting the sales occurred near intermediate peaks relative to recent trading range.